Future Directions in the Management of Hepatocellular Carcinoma

EP: 1.The Evolving Landscape of Hepatocellular Carcinoma

EP: 2.Atezolizumab plus Bevacizumab in the Treatment of Unresectable HCC

EP: 3.AASLD 2023 Updates: HIMALAYA Trial for uHCC

EP: 4.Efficacy and Safety Outcomes in Combination Immunotherapy for uHCC

EP: 5.Real-World Data and Impact on Treatment Selection in uHCC

EP: 6.Additional Data Updates from AASLD 2023

Now Viewing

EP: 7.Future Directions in the Management of Hepatocellular Carcinoma

This is a video synopsis/summary of a Post-Conference Perspectives featuring Anwaar Saeed, MD, and Amit Singal, MD, MS.

In conclusion, Singal and Saeed express excitement over the rapid evolution of treatment options now providing survival benefit across multiple lines of therapy for patients with advanced hepatocellular carcinoma (HCC). This allows consideration of third-line therapy for some patients where none previously existed. Singal notes the phase 3 data demonstrating nearly 25% 4-year overall survival rates truly represents a paradigm shift.

Looking ahead, both physicians are eager to see immunotherapy and targeted therapies moved into earlier settings like the adjuvant and neoadjuvant space, as well as combination therapies for intermediate-stage disease. Equally important is ensuring HCC management utilizes multidisciplinary inputs, as this collaborative approach correlates with better outcomes.

Beyond the perioperative arena, Saeed highlights several other categories of emerging data worth following. These include chimeric antigen receptor T-cell therapy, intratumoral vaccines, bispecific antibodies engaging multiple immune checkpoints, and bridging strategies to transplant. She agrees the future looks bright.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.